Enlivex Therapeutics Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ENLV Nasdaq 2830 www.enlivex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enlivex Therapeutics Ltd.

Nasdaq biotech firm bets $212m on new Arbitrum-based prediction market - Nov 25th, 2025 10:14 am
Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120% - Nov 24th, 2025 2:51 pm
BC-Most Active Stocks - Nov 24th, 2025 8:30 am
Microcap Biotech Firm Raises $212M for Prediction Market Token Treasury Strategy - Nov 24th, 2025 6:00 am
EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play - Nov 24th, 2025 5:46 am
Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis - Nov 24th, 2025 4:40 am
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 - Oct 28th, 2025 6:15 am
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Oct 3rd, 2025 7:00 am
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program - Sep 29th, 2025 6:15 am
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Sep 19th, 2025 7:00 am
Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely? - Sep 14th, 2025 8:02 am
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results - Sep 11th, 2025 6:00 am
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - Sep 9th, 2025 6:00 am
Enlivex advances lead cell therapy to Phase IIb in osteoarthritis - Aug 19th, 2025 5:53 am
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis - Aug 18th, 2025 5:45 am
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar - Aug 14th, 2025 6:30 am
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data - Jul 28th, 2025 6:30 am
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Jun 13th, 2025 8:00 am
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology - Jun 10th, 2025 6:30 am
Enlivex Selected to Present at Israeli BioMed 2025 Conference - May 20th, 2025 6:00 am